GENFIT is a company that specializes in the discovery and development of drugs that target rare and life-threatening liver diseases with high unmet medical needs and is a world leader in Acute-on-Chronic Liver Failure (ACLF), with a unique and exciting pipeline of drug candidates.
Our talented team also focuses on Other Life-Threatening Indications, such as Cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA), as well as innovative diagnostic tools for NASH/MASH1 and ammonia.
Our Pipeline
Acute-on-Chronic Liver Failure (ACLF)
5 programs in Acute-on-Chronic Liver Failure (ACLF) and Hepatic Encephalopathy (HE), one of the most common complications of ACLF.
These are all based on differentiated mechanisms of action leveraging complementary pathways.
Other Life-Threatening Indications
2 programs in other life-threatening indications: Cholangiocarcinoma (CCA), and Urea Cycle Disorders (UCD)/Organic Acidemias (OA).
Diagnostic
2 innovative diagnostic tools for NASH/MASH1 and ammonia.
- NIS2+® in NASH/MASH1
- TS-01 for blood ammonia levels
1 At EASL Congress in June 2023 it was announced that nonalcoholic steatohepatitis (NASH) would now be referred to as Metabolic dysfunction-associated steatohepatitis (MASH). Nonalcoholic fatty liver disease (NAFLD) will now be referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). GENFIT is progressively transitioning its documentation over to this new nomenclature and both NASH and MASH terms may appear in our documents during this period